Rezolute Reports $18.2 Million Net Loss and Increased Operating Expenses for Fiscal Quarter Ending September 30, 2025

Rezolute, Inc. reported its financial results for the fiscal quarter ending September 30, 2025, revealing a net loss of $18.2 million, an increase from the $15.4 million loss recorded in the same period last year. The company's total operating expenses rose to $19.8 million, up from $16.9 million in the prior year, primarily driven by increased research and development (R&D) and general administrative costs. R&D expenses amounted to $13.1 million, reflecting a 3% increase from $12.8 million in the previous year, while general and administrative expenses surged by 59% to $6.7 million, attributed to higher compensation and business development costs.

In terms of liquidity, Rezolute reported cash and cash equivalents of $9.1 million and short-term investments in marketable debt securities totaling $143.1 million, bringing total capital resources to $152.2 million. This represents a significant decrease from the previous quarter's total of $175.5 million, largely due to cash used in operating and investing activities. The company utilized $17.4 million in operating activities and $68.5 million in investing activities during the quarter, primarily for the purchase of marketable debt securities. The company has not generated any revenue to date, as it remains focused on clinical trials for its lead product, ersodetug, which is being developed for the treatment of congenital hyperinsulinism.

Strategically, Rezolute is advancing its clinical trials, with the sunRIZE Phase 3 study expected to yield topline data by December 2025. The company is also preparing for the upLIFT Phase 3 study, which targets tumor hyperinsulinism, with results anticipated in the second half of 2026. The company has received various designations from regulatory authorities, including Orphan Drug Designation and Breakthrough Therapy Designation, which may facilitate expedited review processes.

Operationally, Rezolute's employee headcount increased from 41 to 54 in the R&D department, contributing to higher compensation costs. The company has also expanded its market presence, with ongoing efforts to engage in business development activities in preparation for future commercialization of ersodetug. As of September 30, 2025, the company had an accumulated deficit of $422 million, reflecting its ongoing investment in R&D and clinical trials.

Looking ahead, Rezolute's management believes that its current cash and investments will be sufficient to meet its operational needs for at least the next 12 months. However, the company acknowledges the need for additional financing to support its long-term liquidity requirements, particularly in light of upcoming milestone payments related to its licensing agreements with XOMA and ActiveSite. The company remains focused on executing its clinical development plans while navigating the challenges of being a clinical-stage biopharmaceutical entity.